In the past 20 years, the survival of GIST patients has been remarkably prolonged by the introduction of tyrosine kinase inhibitors (TKIs) targeting gene mutations, mostly KIT or PDGFRA. This evidence concerns the gene KIT and gastrointestinal stromal tumor.